RCKT (Rocket Pharmaceuticals) Research & Development: $137.53 Mil (TTM As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Research & Development?

Rocket Pharmaceuticals RCKT +9.25% 30 Research & Development is $137.53 Mil as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rocket Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was $31.45 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $137.53 Mil.

Rocket Pharmaceuticals  (NAS:RCKT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rocket Pharmaceuticals Research & Development Related Terms

Rocket Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Research & Development Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.48 165.57 186.34 171.24 142.02

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.94 42.66 34.07 29.35 31.45
RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $137.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $137.53 Mil mean?
Rocket Pharmaceuticals (RCKT) has a Research & Development of $137.53 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' Research & Development too high?
Rocket Pharmaceuticals' current Research & Development is $137.53 Mil. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Research & Development compare to TENX and DMAC?
Rocket Pharmaceuticals' Research & Development of $137.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current Research & Development is $137.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Research & Development of $137.53 Mil. The current Research & Development is $137.53 Mil. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Research & Development is $137.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price